The present invention relates to a sterile buffered eye topical composition containing metabolites of the fermentation of Lactobacillus pertaining to the species casei or paracasei and for ophthalmic use of the composition in the prevention or treatment of microbial eye infections, eye allergies, vernal keratoconjunctivitis and keratoconjunctivitis sicca and blepharitis.

The present invention relates to a sterile buffered eye topical composition containing metabolites of the fermentation of Lactobacillus pertaining to the species casei or paracasei and for ophthalmic use of the composition in the prevention or treatment of microbial eye infections, eye allergies, vernal keratoconjunctivitis and keratoconjunctivitis sicca and blepharitis.

The present invention provides a cold solution and method for treating obstructive sleep apnea. The cold solution can comprise liquid and/or solid ice particles. In one embodiment, the method comprises delivering a cold solution to target tissue where the target tissue can be fat tissue located in one or more of an airway, a neck, a thorax, a diaphragm, a face, or an abdomen.

The present invention provides a cold solution and method for treating obstructive sleep apnea. The cold solution can comprise liquid and/or solid ice particles. In one embodiment, the method comprises delivering a cold solution to target tissue where the target tissue can be fat tissue located in one or more of an airway, a neck, a thorax, a diaphragm, a face, or an abdomen.

The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

This invention provides a more efficient means for treating inflammatory gastrointestinal diseases using CO. More specifically, the invention provides a composition for preventing and/or treating inflammatory gastrointestinal diseases, the composition comprising carbon monoxide and a solvent, the CO concentration being 800 μM or more.

This invention provides a more efficient means for treating inflammatory gastrointestinal diseases using CO. More specifically, the invention provides a composition for preventing and/or treating inflammatory gastrointestinal diseases, the composition comprising carbon monoxide and a solvent, the CO concentration being 800 μM or more.

Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.